Press Releases | Regeneron Pharmaceuticals Inc.
WEBDupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) Sep 26. Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024. Sep 20.
Regeneron to Report Third Quarter 2024 Financial and Operating …
WEB3 days ago · TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
WEB2 days ago · REGN. With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US label of Dupixent (dupilumab) to treat chronic obstructive ...
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBAug 1, 2024 · Regeneron is shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling Regeneron to identify innovative targets and complementary approaches to potentially treat or cure diseases.
Regeneron Announces Formation of Regeneron Cell Medicines …
WEBJan 30, 2024 · Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline.
Novel Regeneron Bispecific Antibodies Show Encouraging Anti …
WEBNovel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors. First-in-class Phase 1 data presented at ESMO for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer.
Regeneron Announces Encouraging Topline Phase 2 Data of High …
WEBAug 24, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA ® …
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic …
WEB2 days ago · Currently, Regeneron's stock is trading at $1,063.05, up 2.22 percent, and Sanofi's stock is trading at $57.90, up 1.60 percent on the Nasdaq. SHARE THIS POST FACEBOOK
Regeneron, Sanofi Get FDA OK of Dupixent for COPD — Update
WEB2 days ago · RBC said it sees an ultimate world-wide COPD sales opportunity topping $6.5 billion, bringing overall Dupixent sales to more than $26 billion at their peak. Tarrytown, N.Y., biotechnology company ...
Regeneron (REGN) Set for Monthly Drop on Amgen (AMGN) …
WEB2 days ago · September 27, 2024 at 10:48 AM EDT. Save. Regeneron PharmaceuticalsInc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that opens the door to an early launch ...